Global Hospital Acquired Disease Testing Market Size By Test Type (Urinary Tract Infection, Pneumonia, Bloodstream, Surgical Site), By Competitive Landscape, By Geographic Scope And Forecast

Hospital Acquired Disease Testing Market Size And Forecast

Hospital Acquired Disease Testing Market size was valued at USD 7.2 Billion in 2020 and is projected to reach USD 12.3 Billion by 2028, growing at a CAGR of 7% from 2021 to 2028.

The rising number of patients with nosocomial infections, the government’s increasing number of regulations penalizing hospitals, extended hospitalization and antibody resistance, the growth of the medical tourism industry, and the prevalence of modernized healthcare infrastructure are some of the major and impactful factors that will likely boost the growth of hospital-acquired diseases. The Global Hospital Acquired Disease Testing Market report provides a holistic evaluation of the market. The report offers a comprehensive analysis of key segments, trends, drivers, restraints, competitive landscape, and factors that are playing a substantial role in the market.

Global Hospital Acquired Disease Testing Market Definition

Infections or diseases that start in a hospital are referred to as nosocomial. Such infections can be contracted even if a person is close to a nursing home, rehabilitation facility, hospital, or another clinical setting. HAIs are most commonly contracted in intensive care units (ICUs) and emergency departments (ERs). The incubation time for these diseases typically ranges from 48 hours to four days after a person is admitted. The lack of basic cleanliness in hospital settings by internal employees is a major contributor to the spread of hospital-acquired infections. Another factor could be poor maintenance, hospital staff complacency, or an increase in multi-drug resistance pathogens (MDROs).

Pneumonia, primary bloodstream infections, urinary tract infections, and other nosocomial infections are among the most prevalent. In many cases, these nosocomial infections have been linked to the patients’ microbiome. It occurs when the protective skin layer comes into contact with potential hazards, resulting in infection, particularly after surgical procedures. For the diagnosis of nosocomial infection, health care workers, particularly clinical laboratory technologists, use Hospital-Acquired Disease/Infection (HAI) testing. HAI is also known as a nosocomial infection since it is contracted in hospitals or clinical settings like rehab centers and nursing homes.

Pathogens were prevalent in patients with a conciliated immune system cause HAI in a large number of cases. It is detected in the patient’s microbiome when the protective layer of skin comes into contact with potential pathogens, resulting in infection, most commonly following surgical procedures and healthcare staff neglect. Because of the high mortality and morbidity, as well as the mounting demand from governing authorities and the related management expenses, clinicians must make exact HAI diagnoses to provide effective healthcare. Hospital-acquired infections can be avoided by following rigorous protocols and using less intrusive technology that needs to be monitored by healthcare workers while the patient is being treated.

Global Hospital Acquired Disease Testing Market Overview

The market for hospital-acquired disease testing is growing at double-digit rates right now. There has been a huge increase in the number of health care facilities around the world, fueled by expanding population and upgrading of healthcare infrastructure. As a result, the number of HAIs is on the rise, pushing up the demand for hospital-acquired disease testing. Furthermore, microarrays, polymerase chain reaction (PCR), real-time location systems (RTLSs), and solid-phase hybridization are now available on the market as a result of enhanced technology and scientific advancements for preventing, diagnosing, and monitoring HAIs. HAIs can be easily prevented in both patients and staff using techniques like RTLS. Other factors driving the market’s growth include increasing patient awareness of HAIs and governments establishing policies that punish hospitals with a high prevalence of HAIs.

Government laws governing molecular biology-based diagnostics, as well as a lack of awareness about hospital-acquired diseases among people in underdeveloped nations, would likely serve as market barriers in the expansion of hospital-acquired illness testing throughout the projection period. The growing need for high capital, combined with a scarcity of experienced individuals, will be the market’s biggest and most pressing obstacle. On the other hand, the advancement of various technologies, as well as an increase in the number of firms engaged in research & development, will create several chances for the Hospital Acquired Disease Testing Market to grow throughout the forecast period. The lack of basic cleanliness in hospital settings by internal employees is a major contributor to the spread of hospital-acquired infections. Another factor could be poor maintenance, hospital staff complacency, or an increase in multi-drug resistance pathogens (MDROs).

Pneumonia, primary bloodstream infections, urinary tract infections, and other nosocomial infections are among the most prevalent. In many cases, these nosocomial infections have been linked to the patients’ microbiome. It occurs when the protective skin layer comes into contact with potential hazards, resulting in infection, particularly after surgical procedures. An increasing percentage of patients are developing infections acquired in hospitals. Furthermore, the advancement of healthcare infrastructures, as well as the introduction of infection surveillance solutions and systems that indicate risks and action plans to control these diseases, are likely to fuel market expansion. The demand for Hospital Acquired Disease Testing is predicted to grow as a result of technology advancements in therapeutic and diagnostic applications, as well as the increased incidence of chronic diseases.

The presence of infected patients, as well as contaminated linens, air droplets, and hospital equipment, causes the majority of patients to develop HAIs when they are admitted to emergency rooms (ERs) or intensive care units (ICUs). The number of healthcare institutions has increased around the world in recent years as a result of fast urbanization, rising global population, and upgrading of healthcare infrastructure, increasing in HAI cases. Furthermore, as the healthcare industry continues to innovate, new technologies like microarrays, solid-phase hybridization, polymerase chain reaction (PCR), and real-time locating systems have been created to prevent, diagnose, and monitor HAIs (RTLSs). Inflating morbidity rates, an aging population, a lack of basic hygiene in hospitals, and an increase in multi-drug resistant organisms are some of the additional growth-inducing causes (MDROs).

Global Hospital Acquired Disease Testing Market Segmentation Analysis

The Global Hospital Acquired Disease Testing Market is segmented On the basis of Test Type, And Geography.

Hospital Acquired Disease Testing Market, By Test Type

• Urinary Tract Infection• Pneumonia• Bloodstream• Surgical Site• Other

Based on Test Type, The market is segmented into Urinary Tract Infection, Pneumonia, Bloodstream, Surgical Site, and Others.

Hospital Acquired Disease Testing Market, By Geography

• North America• Europe• Asia Pacific• Rest of the world

Based on Regional Analysis, The Global Hospital Acquired Disease Testing Market is classified into North America, Europe, Asia Pacific, and the Rest of the world. Due to an increase in government initiatives to combat nosocomial infections and the prevalence of favorable reimbursement policies in the region, North America dominates the Hospital Acquired Disease Testing Market, while India and China are expected to grow at the fastest rate in the Asia-Pacific Hospital Acquired Disease Testing Market during the forecast period.

Key Players

The “Global Hospital Acquired Disease Testing Market” study report will provide valuable insight with an emphasis on the global market. The major players in the market are Life Technologies, Luminex Corporation, Diatherix Laboratories, Meridian Biosciences, Qiagen GmbH, Cantel Medical Corporation, F.Hoffmann-La Roche Ltd., Abbott Laboratories, Cepheid, Siemens Healthcare. The competitive landscape section also includes key development strategies, market share, and market ranking analysis of the above-mentioned players globally.

Key Developments

• September 2020 – BioVersys Announces CHF 19 Million Financing to Advance Novel AMR Candidates into Clinical Development. BioVersys AG, a privately owned, multi-asset Swiss pharmaceutical company focuses on developing small molecules for multidrug-resistant bacterial infections with applications in Anti-Microbial Resistance (AMR) and targeted microbiome modulation.

• April 2018 – Nosocomial Vaccine Corporation (NVC), a company that is accelerating research and development of vaccines against nosocomial infections, including those with multiple antibiotic resistance, has announced the publication of a study describing a novel, multivalent vaccine for gram-negative bacterial pathogens.

Report Scope

Top Trending Reports

Research Methodology of Market Research

To know more about the Research Methodology and other aspects of the research study, kindly get in touch with our .

Reasons to Purchase this Report

• Qualitative and quantitative analysis of the market based on segmentation involving both economic as well as non-economic factors• Provision of market value (USD Billion) data for each segment and sub-segment• Indicates the region and segment that is expected to witness the fastest growth as well as to dominate the market• Analysis by geography highlighting the consumption of the product/service in the region as well as indicating the factors that are affecting the market within each region• Competitive landscape which incorporates the market ranking of the major players, along with new service/product launches, partnerships, business expansions and acquisitions in the past five years of companies profiled• Extensive company profiles comprising of company overview, company insights, product benchmarking and SWOT analysis for the major market players• The current as well as the future market outlook of the industry with respect to recent developments (which involve growth opportunities and drivers as well as challenges and restraints of both emerging as well as developed regions• Includes an in-depth analysis of the market of various perspectives through Porter’s five forces analysis• Provides insight into the market through Value Chain• Market dynamics scenario, along with growth opportunities of the market in the years to come• 6-month post sales analyst support

Customization of the Report

• In case of any please connect with our sales team, who will ensure that your requirements are met.